
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Σκοπός του Ιntelligence-pharma είναι να σας ενημερώνει για τις τελευταίες τάσεις και αναλύσεις σχετικά με τον ταχέως μεταβαλλόμενο κόσμο του φαρμάκου.
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share
Upcoming events – Cancer readouts for Merck & Co and Seattle
Regeneron’s Libtayo is chugging along in skin cancer. Next stop? First-line lung
Pfizer, Merck KGaA’s Bavencio takes a hit with second ovarian cancer failure
Merck takes a back seat on CAR-T, handing assets to Intrexon
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Merck KGaA and Pfizer’s Checkpoint Inhibitor Fails in Late-Stage Ovarian Cancer Study
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Επιστροφή στα κέρδη «βλέπει» το 2019 η φαρμακευτική Merck KGaA
The top 10 drugmakers of 2024
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Pfizer, Merck Combination Therapy Shows Significant Improvement in Phase III
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Fresh from the annual meeting of the American Society of Clinical Oncology in Chicago where pharmaceutical companies highlighted their pipelines and products, what is the outlook for the cancer-drug … Continue Reading Strong Growth for the Oncology-Drug Market